Achaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per Share
Wall Street analysts expect Achaogen, Inc. (NASDAQ:AKAO) to announce earnings of ($0.79) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Achaogen’s earnings. The lowest EPS estimate is ($0.99) and the highest is ($0.66). Achaogen posted earnings per share of ($1.04) during the same quarter last year, which indicates a positive year over year growth rate of 24%. The business is expected to issue its next earnings report on Tuesday, March 13th.
On average, analysts expect that Achaogen will report full-year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.16) to ($2.92). For the next fiscal year, analysts expect that the business will report earnings of ($3.22) per share, with EPS estimates ranging from ($3.73) to ($2.78). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Achaogen.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $2.09 million. During the same quarter last year, the business earned ($0.41) EPS. The company’s revenue for the quarter was down 96.4% on a year-over-year basis.
In other news, COO Blake Wise sold 3,576 shares of the firm’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total value of $57,180.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 8.36% of the company’s stock.
Several institutional investors have recently made changes to their positions in AKAO. Legal & General Group Plc acquired a new stake in Achaogen during the second quarter worth $168,000. Sigma Planning Corp boosted its stake in Achaogen by 9.6% during the second quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 825 shares in the last quarter. Bank of Montreal Can boosted its stake in Achaogen by 33.3% during the second quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 2,500 shares in the last quarter. Ardsley Advisory Partners acquired a new stake in Achaogen during the second quarter worth $217,000. Finally, JPMorgan Chase & Co. boosted its stake in Achaogen by 691.2% during the second quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 9,677 shares in the last quarter. Institutional investors and hedge funds own 85.81% of the company’s stock.
Shares of Achaogen (AKAO) traded up $1.02 during mid-day trading on Thursday, reaching $11.96. The company’s stock had a trading volume of 1,782,153 shares, compared to its average volume of 860,626. Achaogen has a one year low of $4.82 and a one year high of $27.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99.
WARNING: “Achaogen, Inc. (AKAO) Expected to Post Earnings of -$0.79 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/30/achaogen-inc-akao-expected-to-post-earnings-of-0-79-per-share.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.